BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36927528)

  • 21. Wnt-driven LARGE2 mediates laminin-adhesive O-glycosylation in human colonic epithelial cells and colorectal cancer.
    Dietinger V; García de Durango CR; Wiechmann S; Boos SL; Michl M; Neumann J; Hermeking H; Kuster B; Jung P
    Cell Commun Signal; 2020 Jun; 18(1):102. PubMed ID: 32586342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High levels of SIRT1 expression enhance tumorigenesis and associate with a poor prognosis of colorectal carcinoma patients.
    Chen X; Sun K; Jiao S; Cai N; Zhao X; Zou H; Xie Y; Wang Z; Zhong M; Wei L
    Sci Rep; 2014 Dec; 4():7481. PubMed ID: 25500546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gavage of Fecal Samples From Patients With Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-Free and Conventional Mice.
    Wong SH; Zhao L; Zhang X; Nakatsu G; Han J; Xu W; Xiao X; Kwong TNY; Tsoi H; Wu WKK; Zeng B; Chan FKL; Sung JJY; Wei H; Yu J
    Gastroenterology; 2017 Dec; 153(6):1621-1633.e6. PubMed ID: 28823860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant.
    Veschi V; Mangiapane LR; Nicotra A; Di Franco S; Scavo E; Apuzzo T; Sardina DS; Fiori M; Benfante A; Colorito ML; Cocorullo G; Giuliante F; Cipolla C; Pistone G; Bongiorno MR; Rizzo A; Tate CM; Wu X; Rowlinson S; Stancato LF; Todaro M; De Maria R; Stassi G
    Oncogene; 2020 Jan; 39(5):987-1003. PubMed ID: 31591478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Preliminary Study of miR-144 Inhibiting the Stemness of Colon Cancer Stem Cells by Targeting Krüppel-Like Factor 4.
    Qiu Z; Tu L; Hu X; Zhou Z; Lin Y; Ye L; Cui C
    J Biomed Nanotechnol; 2020 Jul; 16(7):1102-1109. PubMed ID: 33308377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
    Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miRNA-regulated delivery of lincRNA-p21 suppresses β-catenin signaling and tumorigenicity of colorectal cancer stem cells.
    Wang J; Lei ZJ; Guo Y; Wang T; Qin ZY; Xiao HL; Fan LL; Chen DF; Bian XW; Liu J; Wang B
    Oncotarget; 2015 Nov; 6(35):37852-70. PubMed ID: 26497997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling.
    Hwang JH; Yoon J; Cho YH; Cha PH; Park JC; Choi KY
    Int J Cancer; 2020 May; 146(10):2877-2890. PubMed ID: 31605540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer.
    Liao TT; Lin CC; Jiang JK; Yang SH; Teng HW; Yang MH
    Theranostics; 2020; 10(14):6095-6112. PubMed ID: 32483441
    [No Abstract]   [Full Text] [Related]  

  • 31. Lineage tracing and targeting of IL17RB
    Goto N; Fukuda A; Yamaga Y; Yoshikawa T; Maruno T; Maekawa H; Inamoto S; Kawada K; Sakai Y; Miyoshi H; Taketo MM; Chiba T; Seno H
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12996-13005. PubMed ID: 31182574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.
    Katkoori VR; Basson MD; Bond VC; Manne U; Bumpers HL
    Oncotarget; 2015 Sep; 6(29):27763-77. PubMed ID: 26318034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
    Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
    Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of cancer stem cells from different grades of human colorectal cancer.
    Manhas J; Bhattacharya A; Agrawal SK; Gupta B; Das P; Deo SV; Pal S; Sen S
    Tumour Biol; 2016 Oct; 37(10):14069-14081. PubMed ID: 27507615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
    Mangiapane LR; Nicotra A; Turdo A; Gaggianesi M; Bianca P; Di Franco S; Sardina DS; Veschi V; Signore M; Beyes S; Fagnocchi L; Fiori ME; Bongiorno MR; Lo Iacono M; Pillitteri I; Ganduscio G; Gulotta G; Medema JP; Zippo A; Todaro M; De Maria R; Stassi G
    Gut; 2022 Jan; 71(1):119-128. PubMed ID: 33436496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53.
    Malkomes P; Lunger I; Oppermann E; Abou-El-Ardat K; Oellerich T; Günther S; Canbulat C; Bothur S; Schnütgen F; Yu W; Wingert S; Haetscher N; Catapano C; Dietz MS; Heilemann M; Kvasnicka HM; Holzer K; Serve H; Bechstein WO; Rieger MA
    Oncogene; 2021 Jun; 40(25):4352-4367. PubMed ID: 34103685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer.
    Zhan T; Ambrosi G; Wandmacher AM; Rauscher B; Betge J; Rindtorff N; Häussler RS; Hinsenkamp I; Bamberg L; Hessling B; Müller-Decker K; Erdmann G; Burgermeister E; Ebert MP; Boutros M
    Nat Commun; 2019 May; 10(1):2197. PubMed ID: 31097693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering NK-92 Cell by Upregulating CXCR2 and IL-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon Cancer.
    Gao L; Yang L; Zhang S; Ge Z; Su M; Shi Y; Wang X; Huang C
    J Interferon Cytokine Res; 2021 Dec; 41(12):450-460. PubMed ID: 34935484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRISPR/Cas9-based Gene Therapies for Fighting Drug Resistance Mediated by Cancer Stem Cells.
    Dashtaki ME; Ghasemi S
    Curr Gene Ther; 2023; 23(1):41-50. PubMed ID: 36056851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.
    Williams CS; Bernard JK; Demory Beckler M; Almohazey D; Washington MK; Smith JJ; Frey MR
    Carcinogenesis; 2015 Jul; 36(7):710-8. PubMed ID: 25916654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.